Framework to illustrate the interrelationship between universal health coverage, social protection, TB outcomes, and public health and social impact.

<p>Framework to illustrate the interrelationship between universal health coverage, social protection, TB outcomes, and public health and social impact.</p

Indicative TB-related universal access and social protection indicators and targets.

<p>All indicators should be disaggregated by sex and age.</p>a<p>Should be disaggregated for drug-susceptible and drug-resistant TB.</p>b<p>These indicators should be disaggregated by age, sex, and socioeconomic status, or in the case of geographical coverage mapped against poverty mapping.</p><p>NTP, national tuberculosis programme; NA, not applicable.</p><p>Indicative TB-related universal access and social protection indicators and targets.</p

Round 10 HIV proposals that included direct and indirect forms of economic support (Year 1).

<p>APN+  =  Multi-country East Asia and Pacific; CLWHA  =  Children Living with HIV and AIDS; IDUs  =  Injecting Drug Users; MARPS  =  Most At Risk Populations; MSM  =  Men Who Have Sex With Men; OVC  =  Orphans and Vulnerable Children; PLWHA  =  People Living with HIV and AIDS; SW  =  Sex Workers.</p

TB indicators mapped against the preferred attributes of intervention coverage indicators for general universal health coverage monitoring [49].

<p>TB indicators mapped against the preferred attributes of intervention coverage indicators for general universal health coverage monitoring <a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1001693#pmed.1001693-Huseynova1" target="_blank">[49]</a>.</p

The three dimensions of universal health coverage, with the added dimension of financial risk protection against non-medical costs.

<p>Adapted from World Health Report 2010 <a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1001693#pmed.1001693-WHO4" target="_blank">[21]</a>. Elements in red are non-medical costs and additional interventions within health care and beyond to provide financial protection.</p

The development pipeline of new TB drugs.

<p>OBR: optimized background regimen; EBA: Early Bactericidal Activity study; DS-TB: Drug susceptible tuberculosis; MDR-TB: Multi-drug resistant tuberculosis. Sources: the Stop TB Partnership Working Group on New Drugs, 2015—<a href="http://www.newtbdrugs.org/" target="_blank">www.newtbdrugs.org</a>. Details for projects listed can be found at <a href="http://www.newtbdrugs.org/pipeline.php" target="_blank">http://www.newtbdrugs.org/pipeline.php</a> and ongoing projects without a lead compound series identified can be viewed at <a href="http://www.newtbdrugs.org/pipeline-discovery.php" target="_blank">http://www.newtbdrugs.org/pipeline-discovery.php</a>.</p

The development pipeline of new TB diagnostics.

<p>Sources: WHO Global TB Programme, 2015—<a href="http://www.who.int/tb/publications/global_report/en/" target="_blank">http://www.who.int/tb/publications/global_report/en/</a>; Foundation for Innovative New Diagnostics (FIND)— <a href="http://www.finddiagnostics.org/resource-centre/presentations/find_symposium_capetown_2015/index.html" target="_blank">http://www.finddiagnostics.org/resource-centre/presentations/find_symposium_capetown_2015/index.html</a>. Disclaimer: The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization or are preferred over others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.</p